Vimentin, an intermediate filament protein induced during epithelial-to-mesenchymal transition, is known to regulate cell migration and invasion. However, it is still obscure how vimentin controls such behaviors. In this study, we aimed to find a novel integrin regulator by investigating H-Ras-mediated integrin suppression mechanism. Through a proteomic screen using integrin β3 cytoplasmic tail protein, we found that vimentin may work as an effector of H-Ras signaling. H-Ras converted filamentous vimentin into aggregates near nucleus, where no integrin binding can occur. In addition, increased vimentin filaments accessible to integrin β3 tail enhanced talin-induced integrin binding to its ligands by inducing integrin clustering.
INTRODUCTION
Precise regulations of cell-matrix interactions and cell adhesion play pivotal roles in many biological processes, such as cell growth, differentiation, formation of blood vessels, axon guidance, wound healing, immune responses, hemostasis and other important functions (Gumbiner, 1996; Hynes, 2002) . Integrins, heterodimeric transmembrane proteins composed of α and β subunits, are major cell adhesion receptors that control cell adhesion (Hynes, 2002) . Due to importance of integrins in these diverse biological functions and the potential as a target for treatment of many different human diseases caused by improper cell adhesion (Goodman and Picard, 2012) , the regulatory mechanism of integrin-mediated cell adhesion has been studied extensively (Kim et al., 2011b; Shattil et al., 2010) . These efforts have resulted in identification of many integrin regulators that bind to integrin cytoplasmic tails, such as talin (Calderwood et al., 1999; Tadokoro et al., 2003) , filamin (Lad et al., 2008) , Gα13 (Gong et al., 2010) , kindlin (Harburger et al., 2009; Moser et al., 2009 ) and others (Kim et al., 2011b; Ye et al., 2014) .
Talin, one of the best studied integrin activators, consists of an N-terminal ~50 kDa globular head and a ~220 kDa C-terminal rod domain. The talin head domain (THD) can be divided into four subdomains, F0, F1, F2 and F3 (Elliott et al., 2010) , and the F3 subdomain contains the integrin binding site (Calderwood et al., 2002) . The head domain has a 6-fold higher binding affinity than full-length talin for the integrin β tail, suggesting that the integrin binding site in talin is masked in full-length talin (Yan et al., 2001) . In agreement with this, overexpression of THD or talin F2F3 domain (talin F23) activates integrin, while overexpression of full-length talin has little effect on integrin activation (Han et al., 2006) . Thus, the integrin binding site in talin might be unmasked by intracellular signaling during integrin activation (Calderwood, 2004) . One of the small G proteins, Rap1, was suggested to involve in this unmasking process (Han et al., 2006) . Upon activation by protein kinase C, Rap1 is localized to the plasma membrane and recruits its effector molecule, RIAM (Rap1-GTP-interacting adaptor molecule) (Han et al., 2006; Wynne et al., 2012) , which binds to talin to reveal the integrin binding site (Chang et al., 2014; Yang et al., 2014) .
Some studies have found that other small G proteins are also involved in the integrin activation process (Kinbara et al., 2003) . For example, a constitutively active form of R-Ras enhances integrin activation (Zhang et al., 1996) , presumably through the activation of phosphatidyl inositol-3 kinase (Berrier et al., 2000) and/or an integrin binding protein,
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filamin (Gawecka et al., 2010) . In contrast, a constitutively active form of H-Ras is known to suppress integrin activation by activating Raf and its downstream kinase ERK1/2 (Hughes et al., 1997) . These Ras signaling pathways may activate an integrin regulator, other than talin, that can bind to integrins and regulate their function, and regulator binding can be a promising therapeutic target for integrin-mediated diseases. However, unlike the Rap1-mediated integrin activation signaling cascade, the detailed molecular mechanisms of how Ras signaling pathways may activate integrins are still unknown. Thus, we chose the H-Ras signaling pathway and investigated how H-Ras is involved in integrin suppression with the aim to find a novel integrin regulator.
In the effort to find such an integrin regulator, we identified vimentin in its filament form, as an integrin regulator. Involvement of vimentin in integrin-mediated cell adhesion and migration has been demonstrated in many studies (Satelli and Li, 2011) . During the epithelial-to-mesenchymal transition (EMT), when benign epithelial tumor cells turn into highly invasive malignant tumor cells, vimentin expression is induced and even used as a molecular marker for the EMT (Thiery, 2002) . In addition, vimentin-deficient mice have severe defects in the wound healing process (Eckes et al., 2000) . Cellular localization of vimentin filaments connected to focal adhesions, presumably through vimentin-plectinintegrin β3 interaction, also indicates a possible role of vimentin in integrin regulation (Bhattacharya et al., 2009; Eckes et al., 1998; Tsuruta and Jones, 2003) . Moreover, knocking down the expression of vimentin significantly reduced cell adhesiveness under flow condition (Bhattacharya et al., 2009) . In spite of these reports suggesting a role of vimentin in integrin function, the exact molecular mechanism as to how vimentin regulates cell adhesion and migration has remained unclear. In this study, we suggest that vimentin filaments underneath the plasma membrane can provide integrin-attachment sites by direct interaction with integrin tails. These interactions can result in integrin clustering and enhanced integrin-mediated cell adhesion. Thus, our study helps explain how vimentin can control integrin-mediated cellular processes, such as adhesion, migration, and invasion. We also suggest that disrupting integrin-vimentin interaction can be a promising therapeutic to inhibit human diseases caused by unwanted adhesion.

RESULTS
H-Ras signaling suppresses integrin activation by a talin-independent mechanism
We first investigated the relationship between the H-Ras signaling and the well-known talinmediated integrin activation process to gather information on the unidentified effector of the H-Ras signaling. Because unmasking integrin binding site in talin is known to be required for talin-induced integrin activation (Yang et al., 2014) , the H-Ras signaling pathway may exert its effects by regulating a signaling pathway that promotes such unmasking process. To test this idea, we transfected talin F23 into integrin αIIbβ3-expressing Chinese hamster ovary (CHO/αIIbβ3) cells, together with a constitutively active form of H-Ras, H-Ras(G12V). We stained the cells with PAC1, an antibody specific to active integrin αIIbβ3. Although talin F23 can bypass the unmasking process for integrin activation, expression of H-Ras(G12V) still inhibited the talin F23 induced-integrin activation (Fig. 1A,B) suggesting that H-Ras signaling may not be involved in the unmasking process. Next, we examined if H-Ras signaling can directly regulate the affinity of talin for the integrin β tail, e.g. through modification of talin. To this end, we used CHO/RafER, a cell line stably expressing Raf fused to the estradiol receptor that can be activated by 4-OHT to turn on Raf/ERK signaling for integrin suppression (Hughes et al., 1997) . THD and talin F23 expressed in CHO/RafER cells were pulled-down by integrin β1 tail protein-bound beads, but the pull-down efficiency of wild-type talin was reduced (Fig. 1C) . These data support the hypothesis that the integrin binding site is masked in wild-type talin. Importantly, activation of Raf by 4-OHT treatment did not change the interaction between integrin β tail and talin proteins (Fig. 1C) . Thus, HRas signaling may not regulate the affinity of talin for integrin.
As another possible suppressive mechanism, we hypothesized that H-Ras may recruit a competitive inhibitor for talin binding to integrin. If this hypothesis is correct, an excess amount of talin F23 would prevent the binding of the putative competitive inhibitor and overcome the suppression caused by H-Ras signaling. We found that increasing amounts of talin F23, co-expressed with a fixed amount of H-Ras(G12V) in CHO/αIIbβ3 cells, did not overcome this suppression (Fig. 1D) . In contrast, the suppressive effect of an artificial competitive inhibitor, a talin F23(L325R) mutant that binds but does not active integrin (Wegener et al., 2007) , was overcome by overexpression of wild-type talin F23 (Fig. 1D) .
From these observations, we concluded that generation of a competitive inhibitor for talinintegrin interaction may not be the way by which H-Ras suppresses integrin affinity. Instead, Journal of Cell Science • Advance article the inability of excess amount of talin to overcome the H-Ras-mediated suppressive effect suggests that H-Ras can modulate integrin's function in a way that does not change talinintegrin interaction.
The integrin β tail is the primary site for the regulation of integrin affinity by known regulators (Kim et al., 2011b; Shattil et al., 2010) . To determine whether the integrin β tail is required for H-Ras signaling to suppress integrin activation, we constructed a truncation mutant that lacked the β tail: integrin αIIbβ3Δ717. Using this mutant, we tested whether the integrin β tail is involved in H-Ras-mediated suppression of integrin activation. We found that PAC1 binding to αIIbβ3 without the β3 tail, αIIbβ3Δ717, was unchanged by HRas(G12V), while PAC1 binding to wild-type integrin was increased by talin F23 and decreased by H-Ras(G12V), as expected (supplementary material, Fig. S1 ). These results suggest that the integrin β tail is required for the suppressive effect of H-Ras signaling on integrin activation.
H-Ras signaling negatively regulates vimentin-integrin interaction which can control integrin avidity
Results described above suggested that H-Ras may 1) recruit an integrin inhibitor that may bind to the integrin β tail or 2) induce dissociation of an integrin activator from the tail. With the information, we decided to perform a proteomic screen to identify the putative regulator, using β3 tail protein as bait. In the screening, we tried to identify any protein that interacts differentially with integrin in the absence or presence of H-Ras signaling. We found that 4-OHT treatment on CHO/RafER cells inhibited the binding of a 55-kDa protein to β3 tail ( Fig.   2A ), suggesting that the protein might be one of possible H-Ras effectors. Further analysis with 2-dimensional electrophoresis similarly showed that a 55-kDa spot with a pI of ~ 5.0 was predominantly reduced in the 4-OHT-treated condition (Fig. 2B) . Using mass spectroscopy, we identified the 55-kDa protein as vimentin. Western blot analysis using an anti-vimentin antibody revealed that vimentin expressed in CHO/RafER cells was coprecipitated with integrin β tail protein-bound beads, and 4-OHT treatment reduced this binding (Fig. 2C) , confirming results from the proteomics study. The degree of vimentin binding seemed to represent different levels of vimentin in the cell extracts, because vimentin extracted from the 4-OHT-treated cells was also reduced (Fig. 2C) . Indeed, detergent-soluble vimentin was largely reduced when H-Ras(G12V) was co-transfected ( From these results, we hypothesized that vimentin filaments localized near the plasma membrane may positively regulate integrin-ligand interactions, and one of roles of the H-Ras signaling is to induce the translocation of vimentin to the peri-nuclear region, where no vimentin-integrin interaction takes place.
With the hypothesis, we focused on the possible activating effect of vimentin filaments in integrin-ligand interactions. We observed that forced expression of vimentin in the presence of THD caused an increase in PAC1 binding (Fig. 3A) . Therefore, we concluded that vimentin does have a role in enhancing integrin-ligand interactions. In addition, THDinduced integrin activation was significantly reduced in CHO cells stably expressing vimentin shRNA, when compared to control shRNA expressing cells ( Fig. 3A , red line), we suspected that the role of vimentin may be to induce integrin clustering leading to increased avidity for ligand binding, rather than to change affinity state of integrin. PAC1 binding represents the combined effect of integrin affinity and integrin clustering because PAC1 is an immunoglobulin M that forms a pentamer, providing a total of 10 epitope binding sites (Shattil et al., 1985) . Thus, to specifically measure integrin affinity, we used a monomeric ligand, fibronectin 10th Type III repeat (FN10), of which binding is dependent only on integrin affinity (Ye et al., 2013) . Interestingly, we found that vimentin did not enhance THD-induced binding of FN10 ( (Fig. 3D) .
Vimentin head domain binds directly to integrin tail
Vimentin contains a non-structured head domain (H) at the N-terminus, two coiled-coil domains (often denoted as C1 and C2) in the middle, and a C-terminal tail domain (T) (Fig.   4A ) (Chernyatina et al., 2012) . We examined which domain is responsible for integrin binding. We divided vimentin into N-terminal and C-terminal halves at the linker region between C1 and C2, and the binding of these constructs (expressed in CHO cells) to purified maltose binding protein (MBP)-fused integrin β3 tail was tested. We found that the vimentin H-C1 region bound to the β3 tail protein, but C2-T region did not (Fig. 4B) . In subsequent experiments, purified glutathione-S-transferase (GST)-fused vimentin H bound directly to purified β3 tail specifically in a concentration-dependent manner (Fig. 4C) , showing that vimentin can interact directly with the integrin tail through its head domain. Deletion of 13 amino acids at C-terminal end of β3 tail (750, Fig. 4D ) completely blocked the interaction, suggesting that the region is involved in the interaction. In case of vimentin head domain (vimentin H), deletions after 46 th amino acid (46 and 71) did not, but the deletion after 21 th amino acid (21) blocked the interaction (Fig. 4E) . Thus, vimentin (21-45) seems to be critical for the binding.
We thought that the observed vimentin-induced change in integrin avidity might be due to the ability of vimentin to make filamentous structures and provide many integrin binding sites (vimentin H) under the plasma membrane. If that hypothesis is true, overexpression of vimentin H that is incapable of making filamentous structures might compete with endogenous vimentin filaments for integrin binding, thus abolishing the effect on avidity. In agreement with this idea, vimentin H protein inhibited the interaction between endogenous vimentin and purified β3 tail in a concentration-dependent manner (Fig. 4F ). In contrast, vimentin H protein did not compete with other integrin regulators, such as filamin A and talin (Fig. 4F ). In addition, THD-induced β3 TMD tilting was not inhibited by vimentin H in the purified system (supplementary material, Fig. S2 ), confirming again no competition between talin and vimentin. Interestingly, in agreement with the hypothesis above, expression of vimentin H largely inhibited THD-induced PAC1 binding while surface expression of the Journal of Cell Science • Advance article integrin was not altered (Fig. 5A) . Moreover, we observed that expression of vimentin H caused detachment of vimentin filaments from the plasma membrane regions and induced vimentin aggregation near the nuclei, which is very similar to the effect of H-Ras(G12V) (Fig.   5B , asterisk). These results confirm the role of vimentin in regulating integrin-ligand interactions. Moreover, these results also suggest that integrin-ligand interactions are enhanced by the binding of vimentin filaments, not vimentin itself, to integrin.
Changes in vimentin filament organization can regulate integrin-ligand interactions
Because the integrin binding site was mapped to the vimentin H, we assumed that vimentin H-C1 should inhibit the THD-induced integrin adhesiveness just like vimentin H, and C2-T should have no effect. Very surprisingly, we found that both constructs enhanced the THDinduced PAC1 binding (Fig. 5C ), although this observation was less pronounced for H-C1.
Integrin surface expression was not altered by those constructs (Fig. 5C , bar graphs). We examined whether H-C1 or C2-T had an intrinsic activity to increase integrin-ligand interactions. Similar to full length vimentin, neither fragment induced PAC1 binding when expressed without THD (not shown). However, we found that they destroyed the filamentous vimentin structures and induced punctuated vimentin staining patterns throughout the cells (Fig. 5D, arrows) . This pattern is similar to that formed by aggregates of the vimentin filament precursor observed at the lamellipodia of migrating fibroblasts (Goldman et al., 1996; Helfand et al., 2011; Strelkov et al., 2002) or at cell adhesion sites during cell spreading (Correia et al., 1999) . In agreement with our observation, short peptides from the N-or Cterminal region of vimentin (R1 and R2 in Fig. 4A ) induced fragmentation of vimentin filaments by inhibiting vimentin assembly (Goldman et al., 1996; Helfand et al., 2011; Strelkov et al., 2002) . Theoretically, once vimentin filaments are converted into a large number of smaller pieces, the vimentin fragments can be released from the filamentous structure and move more freely to the plasma membrane than vimentin in the filamentous form. In addition, the filaments would contain enough vimentin molecules to mediate integrin clustering. Thus, our interpretation on these interesting phenomena is that reorganization of vimentin filaments into smaller fragments by H-C1 or C2-T may be responsible for the enhanced integrin adhesiveness. If we consider both the positive (by inducing fragmentation of vimentin filaments) and negative (by inhibiting integrin-vimentin filament interactions) effects, the reason why H-C1 induces a weaker integrin-ligand interaction than C2-T (Fig. 5C) may also be explained.
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Overexpression of vimentin H reduces cancer invasiveness
Next, we investigated the role of the vimentin-integrin interaction on cell migration and metastasis. 4T1 cells are derived from a highly invasive mouse breast cancer cell line from the BALB/c strain (Aslakson and Miller, 1992) and expresses integrin β3 (supplementary material, Fig. S3A ). These cells bind to fibrinogen, a ligand of β3 integrin (integrin αVβ3) expressed in non-platelet cells. This binding increased in the presence of THD and vimentin (supplementary material, Fig. S3B,C) , similar to integrin αIIbβ3 (Fig. 3A) . to generate a population of vimentin H-expressing cells (Fig. 6A) . As a control, we also collected GFP-negative cells (Fig. 6A ). Although vimentin expression in both GFP-positive and -negative cells was rarely detected in normal culture conditions, treatment with transforming growth factor (TGF)-β, the signal that induces the EMT (Liu et al., 2012), significantly induced vimentin expression (Fig. 6B ). In our migration assay, both of these cell populations, GFP-negative and -positive cells, show relatively low migration rate in the absence of TGF-β (Fig. 6C ). When treated with TGF-β, there was a 10-fold increase in the migration rate of GFP-negative cells (Fig. 6C,D) . However, in case of GFP-positive cells, the TGF-β-induced migration was largely suppressed (Fig. 6C,D) . Consistent with this result, BALB/c mice that are intravenously injected with GFP-positive 4T1 cells also exhibited a reduction in nodule formation on the lung (Fig. 6E,F 
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DISCUSSION
In this report, we first identified vimentin filaments as novel regulators for integrin function.
Our study suggests that vimentin filaments underneath the plasma membrane have many vimentin H exposed along the filaments, thus can provide many integrin binding sites for integrin clustering which in turn can enhance integrin-ligand interaction (supplementary material, Fig. S4 ). Because integrins localize to the plasma membrane, this interaction is only possible near the plasma membrane. Thus, we suggest that translocation of vimentin to the peri-nuclear region, for example by H-Ras signaling, may have a negative effect on the integrin-ligand interaction. However, due to the experimental difficulty to test the suppressive effect of H-Ras with vimentin filaments kept intact under plasma membrane, we were unable to determine whether the suppressive effect of the H-Ras is solely dependent on the rearrangement of vimentin filaments. Therefore, at the moment, the initial question on how Correia et al., 1999) . In addition, the small fragments similar to those observed in this study (Fig. 5D ) have been suggested to modulate the formation of lamellipodia (Helfand et al., 2011) . According to our study, vimentin filaments in mesenchymal cells may work as a reservoir for integrin regulators; once the filaments are broken into many smaller fragments in the cellular region where increased cell-ECM interaction is required, the fragments are able to modulate cell attachment at the site by increasing integrin avidity (supplementary material, Fig. S4 ). Therefore, our study can These regulators may serve as an alternative way to control the function of integrins indirectly, whereby the mode of action would only target newly formed adhesion and should not have the associated adverse effects. In this regard, we propose that the integrin-vimentin interaction can be a potent target to overcome the current huddle in anti-integrin therapy.
Based on our study, the inhibition of integrin-vimentin interaction significantly reduced the migration as well as metastasis of cancer cells (Fig. 6) . Considering that the role of vimentin we found in our study is to induce integrin clustering and thus to enhance integrin-ligand interaction, blocking the interaction wouldn't perturb pre-existing cell adhesion but will inhibit only new adhesion formation. At the same time, the mechanism of action will not provoke integrin signaling. Therefore, we believe that our study not only explains the role of vimentin in cell adhesion, but also provides a novel therapeutic target for treatment of cell adhesion-mediated diseases, such as metastasis.
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MATERIALS AND METHODS
Cell lines, plasmids and antibodies
CHO cells and 4T1 cells were purchased from the Korean Collection for Type Culture and the American Type Culture Collection, respectively. CHO/RafER and CHO/αIIbβ3 cells were kind gifts from Dr. Mark Ginsberg (University of California San Diego), and they were authenticated by 4-hydroxytamoxifen (4-OHT) responsiveness and D57 binding, respectively, during their use. HA-tagged talin constructs (wild type, head domain, and F2F3 domain),
HA-tagged H-Ras(G12V), integrin αIIb, and integrin β3 constructs (provided by Dr. Mark
Ginsberg, University of California San Diego) were described previously (Han et al., 2006 ).
An untagged version of H-Ras(G12V) was kindly provided by Dr. Young Do Yoo (Korea University). GFP-talin head domain was generated by inserting PCR-amplified THD into pEGFP-C1 (Clontech). Vimentin cDNA was purchased from Korea Human Gene Bank and used for the PCR reactions to generate HA-tagged vimentin H (amino acid number 2-95), head and C1 domains (H-C1, amino acid number 2-254), and C2 and tail domains (C2-T, amino acid number 255-466) constructs in pcDNA3, as well as GST-fused vimentin H in pGEX4T-1 (GE Healthcare). To generate the His-pMAL/β3 tail construct for purification of maltose binding protein (MBP)-β3 tail protein, the integrin β3 tail region was amplified by PCR and cloned into BamHI/XhoI sites of His-pMAL vector (provided by Dr. Hyun Kyu Song, Korea university). Short hairpin RNA (shRNA) against vimentin was generated by ligation of annealed oligonucleotide containing the target sequence (5'-AATACCAAGACCTGCTCAATC-3') into a lentivirus vector, pLKO.1 (Addgene). Its scrambled sequence (5'-GCAATGCATGCCATACTAACA-3') was used to generate control shRNA construct. These lentivirus vectors were transfected into Lenti-X 293T cell line (Clonetech) to generate lentivirus particle as previously described (Kim et al., 2012) .
Complex-specific integrin αIIbβ3 antibody (D57, 10 g/ml for flow cytometry), activationspecific αIIbβ3 antibody (PAC1, mouse ascetic fluid, 1/400 dilution for flow cytometry), and anti-integrin β3 tail antiserum (Rb8275, rabbit serum, 1/1,000 for western blot) were provided by Dr. Mark Ginsberg. Anti-vimentin (Sigma-Aldrich, V6389, 1/1,000 dilution for western blot, 1/100 for cytochemistry), anti-HA (Santa Cruz Biotechnology, sc-805, 1/1,000 dilution for western blot, 1/100 for cytochemistry), anti-β actin (Santa Cruz Biotechnology, sc-130656, 1/1,000 dilution for western blot), anti-GAPDH (Santa Cruz Biotechnology, sc-20357, 1/500 dilution for western blot), anti-GFP (Santa Cruz Biotechnology, sc-9996, 1/200
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antibodies were obtained commercially.
Protein purification
To prepare monovalent ligand for integrin αIIbβ3, fibronectin 10th Type III repeat (FN10) was used as previously described (Ye et al., 2013) . Briefly, pGEX-6P-1 vector containing FN10 was introduced into E.coli strain BL21-DE3 and protein was expressed by adding IPTG to the culture. Expressed GST-FN10 was purified using glutathione sepharose 4B
(GS4B, GE Healthcare) according to the manufacturer's instructions. The elution buffer was exchanged to PreScission protease cleavage buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, pH 7.5) using Zebra TM spin desalting columns (Thermo Scientific), and the purified proteins were incubated with PreScission protease (GE Healthcare) at 4 ºC overnight to remove GST. The free GST was removed by incubating the mixture with GS4B
for 6 hours at 4ºC. The flow-through was loaded to the desalting column equilibrated with PBS for the biotinlyation reaction using EZ-Link NHS-Biotin (Thermo Scientific). To prepare the multimeric ligand, purified GST-FN10 was first biotinylated and then incubated with 4-fold molar excess of 1,11-bis(maleimido)triethylene glycol ((BM(PEG)3, Thermo Scientific) at room temperature for 1 h to allow cross-linking events to occur. The reaction was treated with 20 mM DTT and incubated for 15 min at room temperature to quench all unreacted reagent, followed by a desalting step. MBP-β3 tail protein was purified from BL21-DE3 transformed with His-pMAL/β3 tail using amylose resin (New England BioLabs) according to manufacturer's guide. Similarly, GST-Vimentin H protein was purified from BL21-DE3 transformed with pGEX4T-1/Vim-H using GS4B.
Pull-down assay
CHO cells transfected with various vimentin constructs were lysed with a lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM HEPES, pH 7.4, protease inhibitor cocktail (Roche)).
Cell lysates were incubated for 20 min at 4ºC with agitation, homogenized by passing through three times through a 26-gauge needle, and then clarified by centrifugation at 14,000 rpm for 20 min. The cell lysates (or GST proteins as indicated) were added with purified MBP-fused integrin β3 tail (or GST-vimentin H protein) and incubated for 2~16 h at 4 ºC with agitation. The mixture were further incubated with amylose resin (or GS4B) for 2 h. 
Cell imaging
CHO cells on gelatin-coated cover glasses were fixed with 3.7% formaldehyde, and then permeabilized with phosphate-buffered saline (PBS) containing 0.1% Triton X-100 (PBS-t).
After treatment with a blocking solution (10% goat serum, 0.5% gelatin in PBS-t), cells were by using a charge-coupled device camera (DS-Qi2, Nikon) and deconvoluted by using NISElements AR (Nikon).
Cell migration assay
Upper chambers of a Transwell ® culture plate with 8 μm pores (Corning) were incubated with 10 g/ml fibrinogen in PBS for overnight. 4T1 cell suspension (5 × 10 4 cells/ml) was placed on the chamber, and cells were allowed to migrate through membrane pores during incubation at 37ºC in 5% CO2 for 20 h. Next, cells were fixed and stained with Cell Staining Solution (Cell Biolabs). After washing with PBS, the images of migrated cells on the opposite side of the membrane were captured by an inverted microscope (Motic AE2000). The number of migrated cells in each field was counted and the average number of triplicate samples was displayed as a bar graph with s.e.m.
In vivo metastasis assay
7-week-old female BALB/c mice were purchased from Orient Bio, Korea. Approximately 10 6 GFP-negative or -positive 4T1 cells in 100 µl PBS were injected into the tail veins of the mice (n=5 per each condition). After two weeks, all mice were euthanized with cervical dislocation and isolated lungs were frozen at -80ºC before taking pictures with a digital camera. All the nodules displayed in the pictures were counted to generate the scatter plots. 
